No Data
No Data
No Data
No Data
No Data
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
WALTHAM, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter
Apellis PharmaceuticalsApr 23 00:00 ET
Unusual Options Activity: COHR, APLS and Others Attract Market Bets, COHR V/OI Ratio Reaches 294.1
EST Apr 19th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trend
moomoo NewsApr 19 16:30 ET
Selling Apellis Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Even though Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has fallen by 15% over the past week , insiders who sold US$7.9m worth of stock over the past year have had less luck. Given that the average s
Simply Wall StApr 18 08:41 ET
Wells Fargo Remains a Hold on Apellis Pharmaceuticals (APLS)
TipRanksApr 18 06:45 ET
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
TipRanksApr 18 01:10 ET
Apellis Pharmaceuticals Is Maintained at Neutral by Wedbush
Apellis Pharmaceuticals Is Maintained at Neutral by Wedbush
Dow JonesApr 17 12:37 ET
No Data
No Data